PRODUCTS CENTER

PRODUCT

API List Loaction：home > product > result

Disclaimer: Products within validity are not offered for sale to the restricted area.
API List（Download PDF）

Therapeutic Area S/N API  CAS No. Remarks
Oncology 1 Pazopanib Hydrochloride
635702-64-6
Technical Package
（Base：444731-52-6）
2 Trametinib Dimethyl Sulfoxide
1187431-43-1
Technical Package
（Base：871700-17-3）
3 Axitinib 319460-85-0 Technical Package
4 Dabrafenib Mesylate
1195768-06-9
Technical Package
（Base：1195765-45-7）
Respiratory 5 Vilanterol Trifenatate
503070-58-4
Technical Package
（Base：503070-34-8）
6 Umeclidinium Bromide 869113-09-7 Technical Package
7 Indacaterol Maleate
753498-25-8
Technical Package
（Base：312753-06-3）
Anti-Viral 8 Dolutegravir Sodium
1051375-19-9
Technical Package
（Base：1051375-16-6）
9 Cabotegravir Sodium
1051375-13-3
In Development
（Base：1051375-10-0）
Hematologic 10 Eltrombopag Olamine
496775-62-3
Technical Package
（Base：496775-61-2）
Skeletal musculature 11 Etoricoxib 202409-33-4 In Development
12 Celecoxib 169590-42-5 USDMF
Ophthalmology 13 Bimatoprost 155206-00-1 In Development
14 Tafluprost 209860-87-7 In Development
15 Travoprost 157283-68-6 In Development
16 Latanoprost 130209-82-4 In Development
APIs 17 Eltrombopag Olamine 496775-62-3 US DMF 38914 NMPA Approval Y20230000603
18 Trametinib (DMSO) 1187431-43-1 Validation  & Registration in 2025
19 Dabrafenib  Mesylate 1195768-06-9 Validated WC Available
20 Ibrutinib (Form A) 936563-96-1 NMPA CDE Y20230001268
21 Tepotinib Hydrochloride 1100598-32-0 Validated  & registration in 2025
1946826-82-9
22 Etrasimod Arginine 1206123-37-6 Under Validation
1206123-97-8
23 Fezolinetant 1629229-37-3 Under Validation
24 Sparsentan 254740-64-2 Pilot
25 Maralixibat HCl 228113-66-4 Under R&D
26 Capivasertib 1143532-39-1 Pilot
Excipient 27 Salcaprozate Sodium (SNAC) 203787-91-1 Validation  & Registration in 2025
28 SM-102 2089251-47-6 R&D
29 ACL-0315 2036272-55-4 R&D